<SEC-DOCUMENT>0001104659-21-002680.txt : 20210111
<SEC-HEADER>0001104659-21-002680.hdr.sgml : 20210111
<ACCEPTANCE-DATETIME>20210111070040
ACCESSION NUMBER:		0001104659-21-002680
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210111
FILED AS OF DATE:		20210111
DATE AS OF CHANGE:		20210111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		21519071

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm212709d1_6-k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of January 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number 001-39446&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)
 &nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 20-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FORM
40-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">YES&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &ldquo;Yes&rdquo; is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 11, 2021, CureVac N.V. (the
 &ldquo;Company&rdquo;) issued a press release announcing the publication of preclinical data demonstrating the response of its
COVID-19 vaccine candidate, CVnCoV, in non-human primates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Form 6-K (including
Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &ldquo;Exchange
Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 53%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 23%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Franz-Werner&nbsp;Haas,&nbsp;LLD,&nbsp;LLM</FONT></TD>
    <TD STYLE="vertical-align: top; width: 23%; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: January 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 86px; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 10px; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 5pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 5pt"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated January 11, 2021.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm212709d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0">&nbsp;<IMG SRC="image_001.gif" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac&rsquo;s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated
Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Data provided further evidence on immunogenicity and protective efficacy of CVnCoV</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Induction of robust antibody and T cell responses at comparable dose tested in clinical trials</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Full lung protection of CVnCoV-vaccinated animals during SARS-CoV-2 challenge infection </I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>T&Uuml;BINGEN, Germany/ BOSTON, USA &ndash; January 11,
2021 &ndash;</B> CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines
based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of
robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. Furthermore, rhesus macaques
were shown to be protected from challenge infection with SARS-CoV-2 following vaccination with 8&micro;g of CVnCoV. The data provided
important evidence on the immunogenicity and protective efficacy of CVnCoV at low doses, supporting the ongoing international
clinical Phase 2b/3 efficacy study applying a 12&mu;g dose. The full manuscript of the preclinical data is available on the pre-print
server <FONT STYLE="color: Blue"><U>bioRxiv</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;These data further strengthen the protective
profile of our lead COVID-19 vaccine candidate, CVnCoV, and complement our recently published preclinical findings,&rdquo;
said Dr. Mariola Fotin-Mleczek, Chief Technology Officer of CureVac. &ldquo;Full protection of the lungs of vaccinated
animals supports CVnCoV&rsquo;s potential in protecting humans from the devastating effects the virus has. We are very
encouraged to see that CVnCoV exihibits its protective efficacy already at a low dose, which is even lower than the dose we
advanced into late-stage human clinical testing.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Within the study, CVnCoV was tested in rhesus macaques at 8&micro;g
per dose following a two-dose vaccination schedule at day 0 and day 28. Robust humoral and cellular immune responses include high
levels of spike protein and RBD specific binding, virus neutralizing antibodies and T cells. Upon challenge infection, vaccinated
animals showed a strongly reduced viral load in the upper respiratory tract (nose and throat) and full protection of the lower
respiratory tract (lungs), where the virus was not detectable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>About CVnCoV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">CureVac began development
of its mRNA-based COVID-19 vaccine candidate in January 2020. The vaccine is an optimized, non-chemically modified mRNA, encoding
the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nano Particles (LNPs).
Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. Phase 1 interim data reported in November
2020 showed that CVnCoV was generally well tolerated across all tested doses and induced strong antibody responses in addition
to first indication of T cell activation. The quality of immune response was comparable to recovered COVID-19 patients, closely
mimicking the immune response after natural COVID-19 infection. The data supported CureVac&rsquo;s decision to advance a 12&micro;g
dose into its current pivotal Phase 2b/3 study, the HERALD study, which started in December 2020. Clinical trial material is provided
by the company&rsquo;s substantial production capacities for mRNA vaccines at its headquarters in T&uuml;bingen, supported by the
current expansion of manufacturing capacities in Europe, allowing broad-scale manufacturing of CVnCoV for potential commercial
supply preparedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white"><B>About CureVac</B><BR>
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise
in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology
is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of
fighting a broad range of diseases. Based on its proprietary technology, the company has built a deep clinical pipeline across
the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its
initial public offering on the New York Nasdaq in August 2020. It is headquartered in T&uuml;bingen, Germany, and employs more
than 500 people at its sites in T&uuml;bingen, Frankfurt, and Boston, USA. Further information can be found at <FONT STYLE="color: Blue"><U>www.curevac.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thorsten Sch&uuml;ller, Vice President Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +49 7071 9883-1577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Blue; background-color: White"><U>thorsten.schueller@curevac.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Sarah Fakih, Vice President Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +49 7071 9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M: +49 160 90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>sarah.fakih@curevac.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains statements that constitute &ldquo;forward
looking statements&rdquo; as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including
statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the &ldquo;company&rdquo;)
regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion
of the potency efficacy of the company&rsquo;s vaccine candidate and the company&rsquo;s strategies, financing plans, growth opportunities
and market growth. In some cases, you can identify such forward-looking statements by terminology such as &ldquo;anticipate,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo;
or &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo;
 &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative of these terms or similar expressions. Forward-looking statements are
based on management&rsquo;s current beliefs and assumptions and on information currently available to the company. However, these
forward-looking statements are not a guarantee of the company&rsquo;s performance, and you should not place undue reliance on such
statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative
worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding,
ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory
approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products,
possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition
and consolidation in the company&rsquo;s industry, the effects of the COVID-19 pandemic on the company&rsquo;s business and results
of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide
for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and
uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements.
Many of these risks are outside of the company&rsquo;s control and could cause its actual results to differ materially from those
it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The
company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the
results of any revisions to any such statements to reflect future events or developments, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, please reference the company&rsquo;s
reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR
on the SEC website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#EAF  U '   "'_"TY%5%-#05!%,BXP P$!   A^00      "P
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M?T*EM"R6RK2+4(<%]I02J SQ"'H:RZM^+YZ"'B#HF[/HR*KKQ+<ZD*ATH9\
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M'P@HHX9.5-""*J"@Z#Q#63#5)9.81'LOB8DK7PG04]9BB$Q)"4J>1,230$Q
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H>S[E-$K<;.1&^]H&0?%&](KM;AO$#.-M2)B]3>YA;00!UE!V0   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
